(function(){
			var content_array=["<p><strong>About Adaptive <\/strong><\/p>\r\n<p>Adaptive Biotechnologies Corporation (\"Adaptive\" or the \"Company\") is a pioneer in immunosequencing diagnostics, with a focus in oncology. The Company leverages advances in next generation sequencing (\"NGS\") to profile T-Cell and B-Cell Receptors (\"TCRs\" and \"BCRs\"). This patented breakthrough enables in-depth characterization of the immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis, and monitoring of cancer patients. The Company's first clinical application, <strong>clonoSEQ&trade;<\/strong>, is for monitoring Minimal Residual Disease (\"MRD\") in blood-based cancers. The Company recently launched clonoSEQ&trade; as a CLIA certified Laboratory Developed Test (\"LDT\") in the second quarter of 2013. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care. Adaptive is currently validating additional oncology diagnostics to quantify the presence and clonality of Tumor Infiltrating Lymphocytes (\"TIL\") and to create a reliable measure of \"immunocompetency\" to predict or monitor response to cancer treatments that directly alter the host immune system. Adaptive incubates and validates potential clinical products by offering fee-for-service access to its proprietary immune profiling sequencing technology under the brand name <strong>immunoSEQ&trade;<\/strong>.<\/p>"];
			$("#dvExtra").html(content_array[0]);})();